Long-term follow-up ABO-incompatible adult living donor liver transplantation in cirrhotic patients

[Guest guest]

Long-term follow-up ABO-incompatible adult living donor liver transplantation in cirrhotic patients

Department of Surgery, Hachioji Medical Center, Tokyo Medical University, Hachioji, Tokyo, Japan

Naoto Matsuno, Department of Surgery, Hachioji Medical Center, Tokyo Medical University, 1163 Tatemachi, Hachioji, Tokyo 193-0998, Japan. Tel.: +81-426-65-5611; Fax: +81-426-65-1796; e-mail: mtn@...

Matsuno N, Nakamura Y, Mejit A, Hama K, Iwamoto H, Konno O, Jojima Y, Akashi I, Iwahori T, Ashizawa T, Nagao T. Long-term follow-up ABO-incompatible adult living donor liver transplantation in cirrhotic patients.

Clin Transplant 2007: 21: 638–642. © Blackwell Munksgaard, 2007

Abstract

Abstract: ABO-incompatible liver transplantation is usually contraindicated. The presence in the recipient of preformed anti-A/B antibodies located on endothelial cells raises the risk of antibody-mediated humoral rejection of the graft. We describe four successful cases of steroid withdrawal in adult patients who had living-donor liver transplantation from ABO-incompatible donors. Antirejection therapy included multiple perioperative plasmapheresis, splenectomy, and a triple immunosuppressive regimen with tacrolimus, methylprednisolone (MPSL), and cyclophosphamide or mycophenolate mofetil (MMF). The maintenance dose of immunosuppression did not differ from that of ABO-identical cases. After transplantation, intrahepatic arterial infusion therapy with prostaglandin E1 (PG E1) was used. As a result, all four patients were able to achieve long-term graft survival without steroid use. They all have good liver function and are leading normal lifestyles. Our experience with these four patients suggests the feasibility of controlling humoral rejection and other complications in adult ABO-incompatible living donor liver transplantations with intrahepatic arterial infusion of PGE1, splenectomy, and plasmapheresis with a regular base of immunosuppression protocol to prevent antibody-mediated humoral rejection.